Michael Fichtner

Michael Fichtner

Auto-generated profile, based on publicly available information

Michael Fichtner

Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland University of Medicine and Health Sciences, Dublin 2, Ireland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2019 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
Ian ReynoldsIan Reynolds
Ian Reynolds
MFMichael Fichtner
Michael Fichtner
DMDeborah A. McNamara
Deborah A. McNamara
EKElaine W. Kay
Elaine W. Kay
JPJochen H.M. Prehn
Jochen H.M. Prehn
JBJohn P. Burke
John P. Burke

10 December 2019 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
Ian ReynoldsIan Reynolds
Ian Reynolds
EOEmer O’cOnnell
Emer O’cOnnell
MFMichael Fichtner
Michael Fichtner
DMDeborah A. McNamara
Deborah A. McNamara
EKElaine W. Kay
Elaine W. Kay
JBJohn P. Burke
John P. Burke

9 November 2021 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
ALAndreas Ulrich Lindner
Andreas Ulrich Lindner
MSManuela Salvucci
Manuela Salvucci
EMElizabeth McDonough
Elizabeth McDonough
SCSanghee Cho
Sanghee Cho
XSXanthi Stachtea
Xanthi Stachtea
Jochen PrehnJochen Prehn
Jochen Prehn
Cancer cells’ ability to inhibit apoptosis is key to malignant transformation and limits response to therapy. Here, we performed multiplexed immunofluorescence analysis on tissue microarrays with 373 cores from 168 patients, segmentation of 2.4 million individual cells, and quantification of 18 cell lineage and apoptosis proteins. We identified an enrichment for BCL2 in immune, and BAK, SMAC, and XIAP in cancer cells. Ordinary differential equation-based modeling of apoptosis sensitivity at single-cell resolution was conducted and an atlas of inter- and intra-tumor heterogeneity in apoptosis susceptibility generated. Systems modeling at single-cell resolution identified an enhanced sensitivity of cancer cells to mitochondrial permeabilization and executioner caspase activation compared to immune and stromal cells, but showed significant inter- and intra-tumor heterogeneity.

14 November 2019 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
Ian ReynoldsIan Reynolds
Ian Reynolds
EOEmer O'Connell
Emer O'Connell
MFMichael Fichtner
Michael Fichtner
DMDeborah A. McNamara
Deborah A. McNamara
EKElaine W. Kay
Elaine W. Kay
JBJohn P. Burke
John P. Burke

2 May 2018 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
SKSinéad Kinsella
Sinéad Kinsella
MFMichael Fichtner
Michael Fichtner
OWOrla Watters
Orla Watters
HKHans-Georg König
Hans-Georg König
Jochen PrehnJochen Prehn
Jochen Prehn
Chronic pro-inflammatory signaling propagates damage to neural tissue and affects the rate of disease progression. Increased activation of Toll-like receptors (TLRs), master regulators of the innate immune response, is implicated in the etiology of several neuropathologies including amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. Previously, we identified that the Bcl-2 family protein BH3-interacting domain death agonist (Bid) potentiates the TLR4-NF-κB pro-inflammatory response in glia, and specifically characterized an interaction between Bid and TNF receptor associated factor 6 (TRAF6) in microglia in response to TLR4 activation. We assessed the activation of mitogen-activated protein kinase (MAPK) and interferon regulatory factor 3 (IRF3) inflammatory pathways in response to TLR3 and TLR4 agonists in wild-type (wt) and bid-deficient microglia and macrophages, using Western blot and qPCR, focusing on the response of the E3 ubiquitin ligases Pellino 1 (Peli1) and TRAF3 in the absence of microglial and astrocytic Bid. Additionally, by Western blot, we investigated the Bid-dependent turnover of Peli1 and TRAF3 in wt and bid−/− microglia using the proteasome inhibitor Bortezomib. Interactions between the de-ubiquitinating Smad6-A20 and the E3 ubiquitin ligases, TRAF3 and TRAF6, were determined by FLAG pull-down in TRAF6-FLAG or Smad6-FLAG overexpressing wt and bid-deficient mixed glia. We elucidated a positive role of Bid in both TIR-domain-containing adapter-inducing interferon-β (TRIF)- and myeloid differentiation primary response 88 (MyD88)-dependent pathways downstream of TLR4, concurrently implicating TLR3-induced inflammation. We identified that Peli1 mRNA levels were significantly reduced in PolyI:C- and lipopolysaccharide (LPS)-stimulated bid-deficient microglia, suggesting disturbed IRF3 activation. Differential regulation of TRAF3 and Peli1, both essential E3 ubiquitin ligases facilitating TRIF-dependent signaling, was observed between wt and bid −/− microglia and astrocytes. bid deficiency resulted in increased A20-E3 ubiquitin ligase protein interactions in glia, specifically A20-TRAF6 and A20-TRAF3, implicating enhanced de-ubiquitination as the mechanism of action by which E3 ligase activity is perturbed. Furthermore, Smad6-facilitated recruitment of the de-ubiquitinase A20 to E3-ligases occurred in a bid-dependent manner. This study demonstrates that Bid promotes E3 ubiquitin ligase-mediated signaling downstream of TLR3 and TLR4 and provides further evidence for the potential of Bid inhibition as a therapeutic for the attenuation of the robust pro-inflammatory response culminating in TLR activation.

30 November 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MFMichael Fichtner
Michael Fichtner
EBEmir Bozkurt
Emir Bozkurt
MSManuela Salvucci
Manuela Salvucci
CMChristopher McCann
Christopher McCann
KMKatherine A. McAllister
Katherine A. McAllister
Jochen PrehnJochen Prehn
Jochen Prehn
Colorectal cancer is a molecularly heterogeneous disease. Responses to genotoxic chemotherapy in the adjuvant or palliative setting vary greatly between patients, and colorectal cancer cells often resist chemotherapy by evading apoptosis. Antagonists of an inhibitor of apoptosis proteins (IAPs) can restore defective apoptosis signaling by degrading cIAP1 and cIAP2 proteins and by inhibition of XIAP. Due to the multiple molecular mechanisms-of-action of these targets, responses to IAP antagonist may differ between molecularly distinct colon cancer cells. In this study, responses to the IAP antagonist Birinapant and oxaliplatin/5-fluorouracil (5-FU) were investigated in 14 colon cancer cell lines, representing the consensus molecular subtypes (CMS). Treatment with Birinapant alone did not result in a substantial increase in apoptotic cells in this cell line panel. Annexin-V/PI assays quantified by flow cytometry and high-content screening showed that Birinapant increased responses of CMS1 and partially CMS3 cell lines to oxaliplatin/5-FU, whereas CMS2 cells were not effectively sensitized. FRET-based imaging of caspase-8 and -3 activation validated these differences at the single-cell level, with CMS1 cells displaying sustained activation of caspase-8-like activity during Birinapant and oxaliplatin/5-FU co-treatment, ultimately activating the intrinsic mitochondrial apoptosis pathway. In CMS2 cell lines, Birinapant exhibited synergistic effects in combination with TNFα, suggesting that Birinapant can restore extrinsic apoptosis signaling in the context of inflammatory signals in this subtype. To explore this further, we co-cultured CMS2 and CMS1 colon cancer cells with peripheral blood mononuclear cells. We observed increased cell death during Birinapant single treatment in these co-cultures, which was abrogated by anti-TNFα-neutralizing antibodies. Collectively, our study demonstrates that IAP inhibition is a promising modulator of response to oxaliplatin/5-FU in colorectal cancers of the CMS1 subtype, and may show promise as in the CMS2 subtype, suggesting that molecular subtyping may aid as a patient stratification tool for IAP antagonists in this disease.